

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/7892479>

# Membrane Receptor Probes: Solid-Phase Synthesis of Biotin-Asp-PEG-arvanil Derivatives

ARTICLE *in* ORGANIC LETTERS · MAY 2005

Impact Factor: 6.36 · DOI: 10.1021/ol0502578 · Source: PubMed

CITATIONS

12

READS

27

8 AUTHORS, INCLUDING:



**Abil E Aliev**

University College London

269 PUBLICATIONS 1,658 CITATIONS

SEE PROFILE



**Pui Man Hoi**

University of Macau

40 PUBLICATIONS 339 CITATIONS

SEE PROFILE



**C Robin Hiley**

University of Cambridge

114 PUBLICATIONS 4,176 CITATIONS

SEE PROFILE



**David L Selwood**

University College London

100 PUBLICATIONS 1,662 CITATIONS

SEE PROFILE

# Membrane Receptor Probes: Solid-Phase Synthesis of Biotin-Asp-PEG-arvanil Derivatives


Cristina Visintin,<sup>†</sup> Abil E. Aliev,<sup>‡</sup> Dieter Riddall,<sup>†</sup> David Baker,<sup>§</sup>  
Masahiro Okuyama,<sup>†,||</sup> Pui Man Hoi,<sup>⊥</sup> Robin Hiley,<sup>⊥</sup> and David L. Selwood<sup>\*,†</sup>

The Wolfson Institute for Biomedical Research, Institute of Neurology, and Department  
of Chemistry, University College London, Gower Street, London WC1E 6BT, UK, and  
Department of Pharmacology, University of Cambridge, Cambridge, UK

d.selwood@ucl.ac.uk

Received February 7, 2005

## ABSTRACT



A modular, flexible solid-phase synthetic route for the preparation of biotinylated cross-linking probes of membrane receptors is described. The route utilizes an orthogonal protection strategy employing a Pd[0] cleavable allyl linker attached to the probe via an aspartate residue. The versatility of the method is illustrated through the synthesis of a number of arvanil-derived cannabinoid receptor ligands displaying either a photoaffinity or a chemical cross-linking group.

The biotinylation of small molecules exploits the uniquely tight biotin–avidin interaction for diverse applications such as detection, visualization, and purification/isolation of proteins. Innovative technological developments continue to appear, including the Scavidin gene therapy system for targeting of biotinylated therapeutics,<sup>1,2</sup> extracorporeal affinity adsorption<sup>3</sup> (for removal of radiolabeled antibodies), and biotinylated activity-based probes for chemical proteom-

ics.<sup>4</sup> In this letter, we describe a flexible solid-phase method for the synthesis of biotinylated, cross-linking, small-molecule probes. The synthetic strategy is modular, based on Fmoc peptide synthesis to allow simple variation of subunits. The chemistry is conducted manually, using readily available plastics, and can be carried out in most chemistry laboratories. The methodology should be applicable to a wide variety of biotinylation problems. Previously, biotinylated adenosine 5-triphosphate analogues have been utilized for the enrichment of membranes carrying the P2Y(1) receptor,<sup>5</sup> while bifunctional small-molecule probes (containing biotin and a cross-linking group) have been used to identify binding sites in proteins.<sup>6</sup> We sought to identify a small-molecule probe capable of cross-linking partially characterized can-

<sup>†</sup> The Wolfson Institute for Biomedical Research, University College London.

<sup>‡</sup> Department of Chemistry, University College London.

<sup>§</sup> Institute of Neurology, University College London.

<sup>||</sup> Current address: Mitsubishi Pharma Corporation 1000, Kamoshidacho, Aoba-ku, Yokohama 227-0033, Japan

<sup>⊥</sup> University of Cambridge.

(1) Lehtolainen, P.; Taskinen, A.; Laukkanen, J.; Airenne, K. J.; Heino, S.; Lappalainen, M.; Ojala, K.; Marjomaki, V.; Martin, J. F.; Kulomaa, M. S.; Yla-Herttuala, S. *J. Biol. Chem.* **2002**, *277*, 8545–8550.

(2) Allart, B.; Lehtolainen, P.; Yla-Herttuala, S.; Martin, J. F.; Selwood, D. L. *Bioconjugate Chem.* **2003**, *14*, 187–194.


(3) Wilbur, D. S.; Chyan, M. K.; Hamlin, D. K.; Kegley, B. B.; Nilsson, R.; Sandberg, B. E.; Brechbiel, M. *Bioconjugate Chem.* **2002**, *13*, 1079–1092.

(4) Adam, G. C.; Sorensen, E. J.; Cravatt, B. F. *Mol. Cell Proteomics* **2002**, *1*, 828–835.

(5) Zundorf, G.; Schafer, R.; Vohringer, C.; Halbfinger, E.; Fischer, B.; Reiser, G. *Biochem. Pharmacol.* **2001**, *61*, 1259–1269.

(6) Hosoya, T.; Hiramatsu, T.; Ikemoto, T.; Nakanishi, M.; Aoyama, H.; Hosoya, A.; Iwata, T.; Maruyama, K.; Endo, M.; Suzuki, M. *Org. Biomol. Chem.* **2004**, *2*, 637–641.


nabinoid receptors.<sup>7,8</sup> The endocannabinoid anandamide **1**, SR141716A **2**, and WIN55,212-2 **3** have affinity<sup>9</sup> for these novel receptors (Figure 1), as does arvanil **4**, an anandamide-



**Figure 1.** Cannabinoid ligands.

capsaicin hybrid that activates non-CB<sub>1</sub>, non-CB<sub>2</sub>, and non-VR<sub>1</sub> receptors.<sup>8</sup> Thus, we chose arvanil as the initial ligand for tagging. We identified the 6-hydroxy-4-hexenoate allyl ester linker<sup>10</sup> of Nakahara as being acid and base stable and cleavable under nearly neutral Pd[0] catalysis conditions. The stability of the arachidonate double bonds in arvanil was tested under the Pd[0] cleavage conditions; no isomerization was detected in the olefinic region by NMR (see Supporting Information). In work on the use of biotin-linked reagents for antibody pretargeting, Wilbur<sup>11</sup> established that a proximal aspartate gave molecules resistance to biotinidases in vivo. Incorporation of a proximal aspartate is therefore a desirable feature and also provides a convenient attachment point to the solid phase. The synthesis of the complete linker is shown in Scheme 1. Thus, 6-bromo-hex-4-enoic acid *tert*-


**Scheme 1.** Synthesis of the Allyl Aspartate Linker



butyl ester **5** was cleaved to the acid with TFA and reacted with phenacyl bromide to obtain the ester **7**. The coupling

reaction between **7** and FmocNH-Asp-O<sup>t</sup>Bu in the presence of K<sub>2</sub>CO<sub>3</sub> in DMF gave, in good yield, the orthogonally protected aspartate **8**. After removal of the phenacyl group by treatment with zinc in acetic acid, the acid **9** was reacted with Argogel-NH<sub>2</sub> resin to give the desired aspartate-loaded resin **10**. The synthesis of the arvanil precursor is shown in Scheme 2. We chose the amide NH as the connection point

**Scheme 2.** Synthesis of Arvanil Precursor



to biotin, as it was straightforward synthetically and there was evidence that substitution at this point would not abolish the biological activity.<sup>8</sup> In contrast, the hydroxyl moiety on the aromatic ring seems to be required. Tips protection of *o*-vanillin, **11**, followed by reductive amination with amino-hexan-6-ol provided **12**, Fmoc protection to **13**, and oxidation with RuCl<sub>3</sub>/NaIO<sub>4</sub> gave the required intermediate **14**. To establish the optimum linker length,<sup>12</sup> we needed to be able to vary the distance between the biotin and ligand easily. Fmoc-8-amino-3,6-dioxaoctanoic acid **15** is a convenient PEG spacer molecule. It was easy to synthesize and could be inserted using standard peptide synthesis protocols. In the first instance we prepared three molecular probes, which differed in the number of spacer units **15** used (Scheme 3). Thus, the resin-linked aspartate **10** was treated with 20% piperidine in DMF to remove the Fmoc protection. Then,

(7) Jarai, Z.; Wagner, J. A.; Varga, K.; Lake, K. D.; Compton, D. R.; Martin, B. R.; Zimmer, A. M.; Bonner, T. I.; Buckley, N. E.; Mezey, E.; Razdan, R. K.; Zimmer, A.; Kunos, G. *Proc. Natl. Acad. Sci. U.S.A.* **1999**, *96*, 14136–14141. Ford, W. R.; Honan, S. A.; White, R.; Hiley, C. R. *Br. J. Pharmacol.* **2002**, *135*, 1191–1198.

(8) Di Marzo, V.; Bisogno, T.; De Petrocellis, L.; Brandi, I.; Jefferson, R. G.; Winckler, R. L.; Davis, J. B.; Dasse, O.; Mahadevan, A.; Razdan et al. *Biochem. Biophys. Res. Commun.* **2001**, *281*, 444–451.

(9) Breivogel, C. S.; Griffin, G.; Di, M. V.; Martin, B. R. *Mol. Pharmacol.* **2001**, *60*, 155–163.

(10) Nakahara, Y.; Ando, S.; Itakura, M.; Kumabe, N.; Hojo, H.; Ito, Y.; Nakahara, Y. *Tetrahedron Lett.* **2000**, *41*, 6489–6493.

(11) Wilbur, D. S.; Chyan, M. K.; Pathare, P. M.; Hamlin, D. K.; Frownfelter, M. B.; Kegley, B. B. *Bioconjugate Chem.* **2000**, *11*, 569–583.

(12) Hashimoto, M.; Yang, J.; Holman, G. D. *ChemBiochem* **2001**, *2*, 52–59.


1) 20% Piperidine  
DMF  
2) Biotin, DMF  
NMM, PyBop

1) 50% TFA/  
SiH(C<sub>3</sub>H<sub>7</sub>)<sub>3</sub>  
2) DMF, NMM

**16**

NCCCCOC(=O)C=COC(=O)C(C)OC(=O)N[C@@H](CCCCNC1CCCCC1)C(=O)OCCCCC1CCCCC1


NCCCCOC(=O)C=COC(=O)C(C)OC(=O)N[C@@H](CCCCNC1CCCCC1)C(=O)OCCCCC1CCCCC1



**21.** Resins **19–21**, were coupled under the usual conditions with the acid **14** to give, after Fmoc deprotection, the intermediates **22–24**, respectively. Two cycles of the last coupling reaction, with arachidonic acid, were necessary, using HATU as a coupling reagent in the presence of DIPEA, in DMF. Tips deprotection with triethylamine trihydrofluoride in THF followed by cleavage from the solid support using Pd(PH<sub>3</sub>)<sub>4</sub> and morpholine in CHCl<sub>3</sub> gave **25–27**. These molecular probes were purified by HPLC and characterized using mass spectrometry techniques. For **26**, the

1) DMF, NMM, PyBop  
 Fmoc  $\xrightarrow{\hspace{1cm}}$  2) 20% Piperidine  
 DMF

Biotin  
  
**28** R = a  
**29** R = b



structure was confirmed by two-dimensional  $^1\text{H}$  NMR (see Supporting Information). To consolidate the binding between a small-molecule ligand and its receptor, a covalent cross-link is frequently required.<sup>13</sup> We designed a series of compounds containing a lysine unit, allowing attachment of a thiol-specific group such as maleimide (for cross-linking to a cysteine residue). Alternatively, a benzophenone unit, which is commonly employed for photoaffinity labeling, was incorporated.<sup>14,15</sup> The optimal distance of the cross-linking group from the ligand was explored with a series of four molecules using the spacer **15** as a repeating unit (Scheme 4).

Coupling of the amino acids with **18** gave, following the route described above, four potential cross-linking ligands: **34–37**. Preliminary biological evaluation used a standard cannabinoid CB<sub>1</sub> binding assay employing displacement of [ $^3\text{H}$ ] SR141716A **2** in rat brain membranes. In this case, we are utilizing CB<sub>1</sub> as a model for the novel cannabinoid receptors. When no cross-linker was present, the binding was relatively insensitive to the number of units of **15** (see Table 1 compounds **25–27**). With either the 4-PhCO-phenylalanine or lysine cross-linking groups (compounds **34** and **35**) one unit of **15** was optimal.

**36** also relaxed precontracted rat small mesenteric artery (EC<sub>50</sub> 30 nM), which was in part endothelium-dependent,

(13) Haugland, R. P. Crosslinking and Photoreactive Reagents. In *Handbook of Fluorescent Probes and Research Chemicals*; Spencer, M. T. Z., Ed.; Molecular Probes, Inc.: Eugene, OR; 1995.

(14) Fleming, S. A. *Tetrahedron* **1995**, *51*, 12479–12520.

(15) Li, Y. M.; Xu, M.; Lai, M. T.; Huang, Q.; Castro, J. L.; DiMuzio-Mower, J.; Harrison, T.; Lellis, C.; Nadin, A.; Neduvellil, J. G.; Register, R. B.; Sardana, M. K.; Shearman, M. S.; Smith, A. L.; Shi, X. P.; Yin, K. C.; Shafer, J. A.; Gardell, S. J. *Nature* **2000**, *405*, 689–694.

**Table 1.** Radioligand CB<sub>1</sub> Binding Assay

probe	units of <b>15</b>	cross-linker	IC <sub>50</sub> $\mu\text{M}$
<b>25</b>	1	none	0.7
<b>26</b>	2	none	3.3
<b>27</b>	3	none	1.0
<b>34</b>	1	4PhCOPh	4.0
<b>35</b>	1	Lys	21.4
<b>36</b>	2	4PhCOPh	2.6
<b>37</b>	2	Lys	ND <sup>a</sup>

<sup>a</sup> ND not determined.

sensitive to both capsaicin and capsazepine (showing interaction with vanilloid receptors), and in some preparations it was SR141716A **2** sensitive, indicating interaction with the abnormal cannabidiol receptor.

In summary, we have developed a flexible solid-phase synthesis for biotinylation utilizing a stable allyl-Asp linker. The synthetic method is compatible with a wide range of reaction conditions, including Fmoc and Boc peptide chemistry, and should have wide applicability.

**Acknowledgment.** This work was supported by a research grant from the Brain Research Trust (C.V.).

**Supporting Information Available:** Detailed synthetic methods and analytical data. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL0502578